Olopatadine/mometasone
| Combination of | |
|---|---|
| Olopatadine | Selective histamine H1-receptor antagonist |
| Mometasone | Topical corticosteroid |
| Clinical data | |
| Trade names | Ryaltris |
| Pregnancy category |
|
| Routes of administration | Nasal spray |
| ATC code |
|
| Legal status | |
| Legal status | |
Olopatadine/mometasone, sold under the brand name Ryaltris, is a fixed-dose combination medication for the treatment of allergic rhinitis and rhinoconjunctivitis in adults and adolescents twelve years of age and older.[1] It contains olopatadine hydrochloride and mometasone furoate monohydrate.[1] It is sprayed into the nose.[1]
Common side effects include an unpleasant taste (dysgeusia).[1]
It was approved for medical use in Australia in December 2019.[1][2]
References
- ^ a b c d e f g "Ryaltris (olopatadine hydrochloride and mometasone furoate monohydrate) Nasal Spray". Retrieved 25 July 2020.
- ^ "Ryaltris nasal spray approved in Australia". OINDPnews. 20 December 2019. Retrieved 25 July 2020.
External links
- "Olopatadine". Drug Information Portal. U.S. National Library of Medicine.
- "Mometasone furoate". Drug Information Portal. U.S. National Library of Medicine.
 | This drug article relating to the respiratory system is a stub. You can help Wikipedia by expanding it. |